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Abstract
Angiopoietins (Ang) are involved in the remodeling,
maturation, and stabilization of the vascular network.
Ang-4 was discovered more recently; thus, its effect
on angiogenesis and its interplay with other angiogenic
factors have not been equivocally established. The
role of Ang-4 in angiogenesis was tested in Matrigel
chambers implanted into the subcutaneous space of
nude mice. Ang-4 inhibited the angiogenic response of
basic fibroblast growth factor (bFGF), vascular endo-
thelial growth factor (VEGF), and GLC19 tumor cells. In
Matrigel chambers with Ang-4–transfected cells, the
mean response was significantly lower than that of
mock cells. Subcutaneous tumor interstitial fluid pres-
sure (IFP) was significantly lower in Ang-4–transfected
GLC19 tumors than in mock-transfected tumors. IFP
reduction in Ang-4–transfected tumors was compa-
rable to the reduction seen after bevacizumab treat-
ment. In vitro, we examined the effect of recombinant
Ang-4 on endothelial cell migration in Boyden cham-
bers. Human umbilical vein endothelial cell (HUVEC)
migration induced by bFGF and VEGF was inhibited
by Ang-4 to control levels. In conclusion, we show that
rhAng-4, as well as transfection with Ang-4, inhibits
angiogenesis induced by GLC19 tumor cells and that
Ang-4 expression reduces elevated tumor IFP. In ad-
dition, we demonstrate that rhAng-4 inhibits HUVEC
migration and growth factor–induced angiogenesis.
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Introduction
Angiogenesis is considered essential to the growth and
metastasis of solid tumors. It is a complex and dynamic pro-
cess regulated by a delicate balance between angiogenic
stimulators and angiogenic inhibitors that are present in the
microenvironment. The best characterized proangiogenic
factors are vascular endothelial growth factor (VEGF) and
basic fibroblast growth factor (bFGF). Numerous other
proteins are known to play a role in angiogenesis, but less
is known about the factors involved in remodeling and
stabilizing the structure of primitive vessels. In particular,
the first two members of the angiopoietin (Ang) family, Ang-1
and Ang-2, are considered important regulators of vascular
remodeling and maturation. Ang are ligands for the endothelial
cell (EC)–specific receptor tyrosine kinase, Tie-2. Ang-1 bind-
ing to Tie-2 induces receptor tyrosine phosphorylation, which
recruits pericytes and smooth muscle cells into developing
vessels and stabilizes mature vessels [1]. Moreover, Ang-1
confers resistance to leakage induced by VEGF [2]. Ang-1 is
mitogenic for cultured ECs and induces proliferation in a dose-
dependent manner [3]. Ang-2 does not induce Tie-2 phos-
phorylation on binding, but Ang-2 competitively inhibits Ang-1
binding [4,5]. Ang-2 is involved in the destabilization of the
endothelium as part of permanent vascular remodeling in
tumors [4,5]. The plastic state triggered by Ang-2 can lead
to new vessel growth or vessel regression, depending on the
presence of other proangiogenic factors. One theory is that
the Ang-1/Ang-2 ratio in tumors is shifted in favor of Ang-2,
which causes increased vascular plasticity [6]. Ang-1 pro-
motes the in vivo growth of intracerebral gliomas in rats, which
is associated with a well-differentiated and organized vas-
cular structure, whereas overexpression of Ang-2 results in
the opposite phenomenon [7]. In addition, Ang-2 has been
shown to antagonize angiogenesis induced by bFGF and
VEGF [8]. Recently, inhibition of Ang-2 was found to reduce
tumor growth [9]. This is interesting, as previous reports have
shown the antiangiogenic effects of Ang-2. The biologic roles
of Ang-3 and Ang-4 and their effects on the interplay between
multiple angiogenic factors within a tumor mass need clari-
fication. High cytoplasmic expression of Ang-4 has been
reported in human colorectal and gastric adenocarcinomas
[10,11]; moreover, Ang-4 induced human umbilical vein endo-
thelial cell (HUVEC) migration in an in vitro assay [12]. In
mouse corneal assay, Ang-3 and Ang-4 are angiogenic in vivo
[12]. However, overexpression of Ang-3 inhibited angio-
genesis in the pulmonary metastasis of Lewis lung carcinoma
and TA3 mammary carcinoma [13]; thus, only sparse and
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partly contradictory information exists regarding the activi-
ties of Ang-3 and Ang-4, and much remains to be learned
about the biologic activity of the more recently discovered
members of the Ang family [14]. The biologic action of Ang
on tumor growth still remains uncertain and might depend
on the unique mixture of angiogenic factors and their re-
ceptors in the microenvironment.
High permeability and leakage from tumor vessels are
important contributing factors to increased interstitial fluid
pressure (IFP) in solid tumors [15–18]. The overall aim of
the present work was to investigate the effects of Ang-4 on
in vivo angiogenesis. As Ang-1 and Ang-2 are regulators of
vessel permeability and maturation, our aim was also to elu-
cidate the effect of Ang-4 on tumor IFP, as IFP is regulated by
vessel permeability.
Materials and Methods
Cell Cultures
HUVECs were obtained from Clonetics (Brøndby, Den-
mark) and cultured in an endothelial basal medium (EBM) 2
Bulletkit (Cambrex, Vallensbaek, Denmark). Experiments
were performed on cells in passages 4 to 6.
The human small cell lung cancer (SCLC) cell line GLC19
was maintained with RPMI medium (GibcoBRL, Taastrup,
Denmark) supplemented with 10% heat-inactivated fetal
calf serum.
The cells were cultured in a humidified atmosphere with
5% CO2 at 37jC, without the addition of antibiotics.
Growth Factors
The following growth factors were used: recombinant
human bFGF (Sigma-Aldrich, Vallensbaek, Denmark), re-
combinant human VEGF-A (R&D Systems, Abingdon, UK),
and recombinant human Ang-4 (R&D Systems).
Migration Assays
In vitro EC migration was assessed with Boyden chamber
assay. Polycarbonate membranes (Neuro Probe, Inc., Gai-
thersburg, MD) of 8 mm pore size were coated overnight in a
0.1-mg/ml solution of human collagen IV (Sigma-Aldrich).
Serum-free EBM-2 growth medium, with 0.2% bovine serum
albumin and growth factors as chemotactic stimuli, was ap-
plied to the bottom wells of a Neuro Probe AP48 chemotaxis
chamber; a complete Bulletkit medium with serum and growth
factors was used as positive control. In accordance with
standard usage guidelines, coated membranes were applied,
and a cell suspension containing 40,000 cells in serum-free
EBM-2 medium was added to each upper well. After 4 hours
of migration in a humidified chamber at 37jC and 5%CO2, the
chambers were disassembled. The membranes were fixed
in methanol and stained with Giemsa stain (Invitrogen,
Taastrup, Denmark). The stained membranes were attached
to a microscope slide, and cells were wiped off the non-
migrated side of the filter. Migrated cells were counted under
a microscope with a counting grid. All groups were studied
in hexaduplicate in each experiment, and the experiment
was performed thrice. Applied growth factor concentrations
were chosen based on previous studies of EC migration [8].
Real-Time Monitoring of HUVEC Proliferation and Viability
The Real-Time Cell Electronic Sensing (RT-CES) system
(ACEA Biosciences, Inc., San Diego, CA) uses an electronic
impedance readout to noninvasively quantify adherent cell
proliferation and viability in real time.
A 16 device was coated with gelatin (1 mg/ml) for 15 to
30 minutes at 37jC and 5% CO2 in a humidified atmosphere.
Wells were washed twice with sterile water. At t = 0 hours,
50 ml of EBM-2 media with 2% fetal bovine serum (FBS) was
added per well, and background impedance was measured.
Then 5000 cells in 100 ml of culture media were applied per
well. bFGF (10 ng/ml) and VEGF (3 ng/ml) were added
immediately. At t = 5 hours, HUVECs attached, and Ang-4
was added in different concentrations (10, 40, or 200 ng/ml).
Attachment, spread, and proliferation were continuously
monitored every 10 minutes for a period of 24 hours.
The electronic readout of cell sensor impedance was
displayed as an arbitrary cell index unit. The cell index at
each time point was defined as Rn  Rb/Rb, where Rn is the
cell electrode impedance of the well with cells and Rb is the
background impedance of the well with media alone [19].
In addition, HUVEC proliferation was tested in a 96-well
device. HUVECs were seeded, and growth factors were
applied as described above. Cells were fixed and stained
before the photography of the wells. Proliferation was calcu-
lated by computer-assisted cell counting.
Animals
Male 7-week-old athymic nude mice (NMRI-nu/nu) ob-
tained from Taconic M&B (Lille Skensved, Denmark) were
used. The mice were kept in groups of five in individually
ventilated SealSafe cages (Scanbur BK A/S, Karlslunde,
Denmark) and fed sterile food pellets and water ad libitum.
Lighting was controlled in a 12-hour light/dark cycle. Institu-
tional guidelines for animal welfare and experimental con-
duct were followed.
Matrigel Chambers
In vivo, angiogenic response was tested using a
modified Z-chamber angiogenesis assay, as previously
described [8,20].
All groups consisted of 16 to 20 chambers, corresponding
to 8 to 10 animals (two chambers per animal). The animals
were anesthetized using subcutaneous injections of 1 mg/kg
xylazine (Rompun; Bayer, Kgs. Lyngby, Denmark) and
10 mg/kg ketamine (Ketalar; Pfizer, Sollentuna, Sweden) in
an isotonic 0.9% NaCl solution. Immediately before implan-
tation, appropriate portions of BD Matrigel (BD Biosciences,
San Diego, CA) containing the growth factors and/or the
tumor cells to be examined were prepared and kept on ice.
For experiments with tumor cells, 5  106 GLC19 cells per
chamber were resuspended in Matrigel; experiments were
performed on cells in passages 102 to 107. Growth factor–
reduced Matrigel was used for studies involving growth
factors only, whereas standard Matrigel was used for studies
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with tumor cells. Growth factor concentrations were chosen
based on previous studies of bFGF, VEGF, and Ang with
Matrigel chamber assay [8].
Z-chambers (Lab Vision Corporation, Fremont, CA) were
then filled with appropriate Matrigel mixture and implanted
subcutaneously in male nude NMRI mice. Using blunt dis-
section through a 1.5-cm transversal incision in the neck
region of each mouse, a subcutaneous pocket on either flank
of the animal was formed. A chamber was inserted into each
pouch, and the incision was closed with nonresorbable
suture (Ethicon 6-0).
The chambers used were of the type TZ-014, with an
outer diameter of 14 mm, a membrane pore size of 180 mm,
and a chamber volume of approximately 0.2 ml.
Excision
The chambers were well tolerated, and only a few adhe-
sive tissue reactions were observed at the time of removal.
The location of the incision at a distance from the actual
implantation site prevented the rigid chambers from inflicting
mechanical stress on the wounds. No macroscopic signs of
inflammation were observed.
Mice were sacrificed on day 12 (growth factor experiment)
or on day 16 (tumor cell experiment), and the chambers were
excised. The time points were chosen based on pilot studies
showing an appropriate measurable angiogenic response
on days 12 and 16, respectively. Care was taken to remove
any tissue adhering to the outside of the chambers, which
were then placed on a white surface. Using a setup consist-
ing of an Olympus SC-40 microscope (Olympus, Melville,
NY) fitted with a ring lighting system and a Leica DC-150
digital camera (Leica, Bannockburn, IL), the chambers were
photographed from both sides. Images were saved as high-
quality compressed images in JPEG format.
Quantification of Matrigel Chamber Angiogenesis
The quantification procedure was performed as described
previously [14]. Briefly, the image processing software Paint
Shop Pro 8.1 (Jasc Software, Eden Prairie, MN) was used to
select the area of interest (AOI) for each chamber. Subse-
quently, the images were opened with the program Sigma
Scan Pro 5.0 (SPSS Science, Chicago, IL) to detect the total
number of red pixels for each image and then to calculate the
corresponding area. These data were transferred to a
spreadsheet, where the red area of each image was divided
by the total number of pixels in the AOI, yielding the per-
centage of red coloration.
For each group, the mean values of the percentages of
red pixels were calculated.
Histochemistry
After photography, chamber content was excised by cut-
tingnylonmembranesalong the inner rimof thePlexiglas ring.
Chambers for paraffin sections were then fixed in 4%
paraformaldehyde and embedded in paraffin blocks. Cham-
bers for CD31 immunohistochemistry were frozen in pre-
cooled isopentane. Sections were cut, air-dried, fixed in 4%
paraformaldehyde, washed in phosphate-buffered saline
and Tris-buffered saline (pH 7.6), and incubated with 5% rab-
bit serum (X902; DAKO, Albertslund, Denmark) for 30 min-
utes. Incubation with rat anti-CD31 antibodies was carried
out overnight at 4jC. An antibody solution was used in a
0.5-mg/ml dilution (PharMingen 553370; BD Biosciences).
Then, sections were incubated with biotin-conjugated rabbit
antirat immunoglobulin (E468; DAKO) in a 1:600 dilution for
30 minutes and incubated with alkaline phosphatase–
conjugated streptavidin (D396; DAKO) for 30 minutes. The
Fast Red Substrate System (K699; DAKO) was used as
substrate for the alkaline phosphatase reaction. Sections
were counterstained with hematoxylin.
Paraffin sections were used for Ki67 immunohisto-
chemistry. NCL-Ki67p (Novocastra Laboratories, Ltd., New-
castle, UK) was used as a primary antibody in 1:4000 dilution.
Generation of Ang-4 Expression Plasmid and Transfection
A pDrive vector containing the full coding region of Ang-4
(Incyte Easy-to-Spot Human cDNAClone;OpenBiosystems,
Huntsville, AL) was verified by sequencing (MWG biotech
AG, Ebersberg, Germany). The Ang-4 coding region was cut
out by BamHI and XbaI and ligated into the expression vector
pcDNA3.1() (Invitrogen, Taastrup, Denmark). To verify the
construct, HEK293 cells were transfected with the Ang-4
pcDNA3.1() construct or the empty pcDNA3.1() vector
(mock) using Lipofectamine2000 (Invitrogen), according to
the manufacturer’s instructions. After 72 hours, media and
cells were collected, and the expression of Ang-4 in cells and
media was verified by Western blot analysis. Subsequently,
GLC19 cells were transfected with Ang-4 pcDNA3.1 () or
withmock vector, and were verified as described above. After
48 hours, 2 mg/ml G418 was added for the selection of
transfected cells.
Reverse Transcriptase–Polymerase Chain Reaction
(RT-PCR)
Total RNA was extracted with Trizol (Invitrogen) or with
RNeasy minikit (Qiagen, Hilden, Germany), as described by
the manufacturer. cDNA was generated by ThermoScript
cDNA kit (Invitrogen) following the manufacturer’s instruc-
tions. All RT-PCR fragments were amplified using the Ampli-
TaqGold System (Applied Biosystems, Naerum, Denmark)
under the following conditions: 95jC for 5 minutes, 35 cycles
at 95jC for 30 seconds, annealing at 60jC for 1 minute, and
elongation at 72jC for 1 minute. All PCRs were finalized
by a 10-minute elongation at 72jC. A control reaction with
GAPDH primers (sense 5V-AACGGATTTGGTCGTATT-
GGGC-3V and antisense 5V-TAAGCAGTTGGTGGTGCAGG-
3V) was performed to verify the quality of the cDNA before
performing PCR with primers for Ang-4 (368-bp product;
sense 5V-TTCTGTCCACCAACAAGCTG-3V and antisense
5V-CTCTGCACAGTCCTGGAACA-3V).
Western Blot Analysis
Protein was extracted from cell pellets or tissue homoge-
nates with a lysis buffer [50 mM Tris (pH 7.5), 150 mM NaCl,
1% NP-4, 0.1% sodium dodecyl sulfate, 1% (wt/vol) natrium
deoxycholate, 1 mM Na3VO4, 1 mM dithiothreitol, complete
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protease inhibitors (Roche Diagnostics, Hvidovre, Den-
mark)] and homogenized by sonication. Protein concentra-
tions were determined using BCA protein assay (Pierce,
Rockford, IL). Twenty micrograms of protein was separated
on NuPage Bis-Tris gels (Invitrogen) and transferred to
nitrocellulose membranes by semidry blotting. Protein de-
tection was performed after blocking in 5% milk powder in
Tris-buffered saline with 0.1% Tween-20 (TBST). The mem-
brane was incubated overnight at 4jC with a primary anti-
body in TBST (0.1 mg/ml Ang-4, AF-964, R&D Systems;
1:80,000 a-tubulin, T-9026, Sigma, Vallensbaek, Denmark)
and with horseradish peroxidase–coupled secondary anti-
body (DAKO) for 1 hour before detection with ECL+ (Amer-
sham). Protein expression was visualized and quantified by
chemifluorescence scanning on a STORM 840 (Molecular
Dynamics, Inc., Sunnyvale, CA). a-Tubulin expression was
used as loading control.
Tumor Xenografts
Xenografts were established by subcutaneous injection of
tumor cells in the flank of nude mice. Cells (5  106) were
mixed with 200 ml of Matrigel before injection. Tumors were
measured thrice a week during tumor growth as two orthog-
onal diameters d1 and d2. Tumor volume was calculated
according to the equation:
V ¼ k=6ðd1d2Þ3=2k
where k is an empirical constant equal to 0.67 [21].
Bevacizumab
Bevacizumab (Avastin; Roche Pharmaceuticals) is an
anti-VEGF humanized monoclonal antibody that binds
VEGF and prevents the interaction of VEGF with its recep-
tors (Flt-1 and KDR) on the surface of ECs [22,23]. Bevaci-
zumab was given as 200-mg intraperitoneal injections thrice a
week, starting on the day before the implantation of Matrigel
chambers or tumor cells.
IFP
Tumor IFP measurements were performed by wick-
in-needle technique [24], with modifications [25]. Briefly, a
23-gauge needle with a 2- to 3-mm side hole 4 to 5 mm from
the tip was filled with five surgical sutures (Ethicon 6-0). A
sensing needle was coupled to a pressure sensor by a wa-
ter column in polyethylene tubing (inner diameter, 0.58 mm)
filled with heparinized saline (70 U/ml). The pressure sensor
was connected to a MacLab/4e (ADInstruments, Ltd., Colo-
rado Springs, CO) through an ML112 bridge amplifier (AD-
Instruments, Ltd.). Pressure data from the sensor were
collected from a MacLab/4e digitizer by SCSI interface using
a personal computer with a PowerLab Chart software v. 4.2
(ADInstruments, Ltd.). The pressure-sensing system was
calibrated against a water column of predefined height be-
fore each experiment, and calibration was checked at the end
of each experiment. Calibration remained stable over time.
Because tumor IFP can vary with tumor size, IFP was
measured only for tumors with a volume of 600 to 1000 mm3
to ensure comparability between groups.
Statistical Analysis
Statistical evaluations of differences between treated and
untreated groups were performed using a two-tailed Mann-
Whitney U test. The software package SPSS 12.0 was used
for statistical analyses, and differences were accepted as
statistically significant at P < .05.
Results
Ang-4 Inhibits EC Migration in Serum-Free and Growth
Factor–Stimulated Conditions
When Ang-4 was added to a serum-free medium, EC
migration in the Boyden chamber assay was reduced in a
dose-dependent manner (Figure 1A); the reduction from 40
to 320 ng/ml was significant (P = .002).
Figure 1. In vitro EC migration in Boyden chambers. (A) Addition of 40 ng/ml Ang-4 to the serum-free medium significantly reduced the number of migrated cells
from 76.2 to 41.5. Further addition of Ang-4 did not result in further inhibition of EC migration. (B) In a separate experiment, the combination of 50 ng/ml bFGF and
16 ng/ml VEGF caused EC migration significantly above the control level (mean, 96.1 vs 50.2 cells/field). This response was significantly inhibited by the addition
of Ang-4 (40 ng/ml). Data are expressed as mean ± SD. Each column represents a mean value of six wells in each group. Migrated cells were counted at
250 magnification.
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A combination of 50 ng/ml bFGF and 16 ng/ml VEGF
significantly stimulated EC migration (P = .014) (Figure 1B).
Further addition of 40 ng/ml Ang-4 to the medium con-
taining bFGF and VEGF significantly inhibited migration
(P = .038) (Figure 1B).
Effect of Ang-4 on EC Proliferation
By means of the RT-CES system, we tested the effect
of Ang-4 on HUVEC proliferation in a low-serum medium
and in a medium with bFGF and VEGF. The combination
of bFGF (10 ng/ml) and VEGF (3 ng/ml) significantly in-
creased HUVEC proliferation (P = .029) (Figure 2A). How-
ever, HUVEC proliferation was not affected by Ang-4 in this
system; neither the proliferation level under low serum con-
ditions (Figure 2B) nor the proliferation induced by bFGF
and VEGF was affected (Figure 2A). Similar results were
obtained by the computer-assisted cell counting of cells
cultured with the same growth factors in 96-well trays (data
not shown).
Growth Factor–Induced In Vivo Angiogenesis in Matrigel
Chambers Is Inhibited by Ang-4
The addition of 750 ng/ml bFGF and 250 ng/ml VEGF to
the Matrigel chambers on implantation induced a mean
angiogenic response of 23% red pixels. This was signifi-
cantly above the control level of 5% (P < .0001) (Figure 3A).
By further addition of Ang-4 (500 ng/ml), the response was
reduced to 11% red coloration, which was significantly less
than the response to bFGF and VEGF alone (P = .014).
Tumor Angiogenesis in Matrigel Chambers Is Inhibited
by Ang-4
Ang-4 expression was evaluated by RT-PCR in a series of
SCLC lines. In four of nine cell lines, a transcript was de-
tected (Figure 6A). The SCLC cell line GLC19 was chosen
for tumor cell studies because of its lack of endogenous
Ang-4 production and its relatively high angiogenic activity
in the in vivoMatrigel chambers in pilot studies. When grown
as subcutaneous xenograft tumors, GLC19 has a relatively
high vessel density and VEGF expression, compared with
other SCLC lines [26].
Chambers with GLC19 tumor cells showed a mean angio-
genic response of 40%, which is significantly above the cell-
free control level of 7% (P < .0001) (Figure 3B). When
1500 ng/ml recombinant Ang-4 was added to tumor cells on
implantation, the mean angiogenic response was signifi-
cantly lower at 25% (P = .015) (Figure 3B). We found no
further inhibition of tumor angiogenesis in the Matrigel cham-
bers with the addition of a larger dose of Ang-4 (3000 ng/ml).
CD31 immunohistochemistry confirmed the widespread
presence of ECs in the chambers with GLC19 tumor cells,
indicating that the observed degree of red coloration does
indeed reflect angiogenesis (Figure 4, A and C). The addition
of Ang-4 to the GLC19 chambers resulted in less red colora-
tion, which also was reflected by a sparser distribution of
CD31+ structures in these chambers (Figure 4, B and D).
To ensure the viability of tumor cells in the chambers, anti-
Ki67 staining was applied to assess proliferation (Figure 4, E
and F ). Ki67 nuclear staining of Matrigel chambers showed
proliferating cells in both untreated GLC19 chambers and
chambers with GLC19 and Ang-4, indicating that reduced
vascularity is caused by a direct effect on angiogenesis,
rather than on cytotoxicity. Proliferation was pronounced
in the periphery of the chambers, close to the membranes,
whereas the center of the chambers showed very little
proliferation. This was the case in chambers with and with-
out Ang-4.
Transfection of GLC19 with Ang-4 Inhibits Tumor
Angiogenesis in Matrigel Chambers
To further evaluate the role of Ang-4, we transfectedGLC19
cells with Ang-4 or with an empty control vector (mock).
The mean angiogenic response in Matrigel chambers with
Figure 2. RT-CES measurements of HUVEC proliferation are shown. The combination of bFGF (10 ng/ml) and VEGF (3 ng/ml) significantly induced HUVEC
proliferation (A and B). There was no significant effect of Ang-4 addition, neither when Ang-4 was applied in combination with bFGF and VEGF (A) nor when Ang-4
was applied as a single agent (B). After 24 hours, proliferation curves level off, and cell growth is no longer exponential. Beyond 24 hours, the bottom of the wells is
completely covered by ECs, and there may be lack of media and growth factors. As expected, the lowest proliferation rate was found in the wells containing FBS
alone, with no growth factors added.
368 Ang-4 Inhibits Angiogenesis and Reduces IFP Olsen et al.
Neoplasia . Vol. 8, No. 5, 2006
mock-transfected GLC19 tumor cells was 46% (Figure 3C). In
Matrigel chambers with Ang-4–transfected cells, the mean
response was 23%, which was significantly lower than the re-
sponse of mock cells (P = .003) (Figure 3C). To demonstrate
the effect of a known antiangiogenic substance in this model
system, mice bearing chambers with mock-transfected cells
were treated with bevacizumab. Similar to transfection with
Ang-4, bevacizumab significantly lowered angiogenic re-
sponse to 29% (Figure 3C).
Ang-4 Transfection Does Not Affect the Growth
of Tumor Xenografts
When Ang-4–transfected and mock-transfected GLC19
cells were grown as subcutaneous tumor xenografts, no dif-
ference in growth rate or growth delay was found (Figure 5A).
To verify if Ang-4 transfection was intact following growth
on mice, tumors were excised for protein isolation. Ang-4 ex-
pression was high in tumors from Ang-4–transfected GLC19
cells (Figure 6B). As a positive control for tumor growth in-
hibition, we used bevacizumab treatment, which significantly
slowed the growth of subcutaneous tumors. We used the
Kaplan-Meier log rank test of time until the tumor volume
was z1000 mm3 (P = .005) (Figure 5A).
Tumor IFP Is Decreased by Ang-4
Tumor IFP was significantly lower in Ang-4–transfected
GLC19 xenografts than in mock-transfected xenografts
(P = .027) (Figure 5B). The mean IFP in the two groups
was 15.6 ± 3.8 and 18.9 ± 5.1 mm Hg, respectively. Further-
more, IFP was significantly lower in bevacizumab-treated
tumors than in mock-transfected controls (P = .006) (Fig-
ure 5B). The mean IFP in bevacizumab-treated tumors was
14.6 ± 4.0 mm Hg.
Discussion
The aim of the present study was to clarify the role of Ang-4
in angiogenesis. The effect of different Ang on the angio-
genic process is complex, as exemplified by Ang-2. Ang-2
stimulates angiogenesis in the corneal model in the pres-
ence of VEGF [27], but it also competes with Ang-1 for the
Tie-2 receptor. VEGF plays an important role in the effects of
Ang-2. Ang-2 is thought to stimulate pericyte detachment
and basal membrane degradation; in the presence of VEGF,
this will allow EC sprouting and migration, facilitating the
early phases of angiogenesis. If VEGF levels are low, the
destabilization of the vessel wall will instead lead to an
antiangiogenic effect of Ang-2.
The Matrigel chamber assay has the advantage of allow-
ing the study of well-characterized combinations of angio-
genic factors. We have previously shown that Ang-2 inhibits
the angiogenesis induced by a bFGF/VEGF growth factor
combination in the Matrigel chamber assay [8]. In the present
study, we found a similar inhibitory effect of Ang-4. Further-
more, this study shows that Ang-4 inhibits EC migration
in vitro and tumor cell– induced angiogenesis in vivo. The
Figure 3. In vivo angiogenic response in Matrigel chambers. (A) Growth
factor – induced angiogenesis in Matrigel chambers. The combination of
750 ng/ml bFGF and 250 ng/ml VEGF induced angiogenesis on day 12
significantly above the control level. Addition of Ang-4 (500 ng/ml) signifi-
cantly inhibited the response. (B) Tumor angiogenesis in Matrigel chambers
induced by GLC19 SCLC cells. Tumor cells induced a highly significant
angiogenic response by 16 days of implantation in Matrigel chambers. The
addition of Ang-4 (1500 ng/ml) to tumor cells significantly inhibited angio-
genic response. (C) Angiogenesis in Matrigel chambers induced by trans-
fected tumor cells. Ang-4– transfected GLC19 cells induced an angiogenic
response that was significantly lower than that of mock-transfected cells.
Bevacizumab treatment of the mock-transfected cells also reduced angio-
genic response. Each column represents a mean value of 18 to 20 chambers
in each group. Data are expressed as mean ± SD.
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Figure 5. GLC19– transfected cells grown as subcutaneous tumors on mice. (A) Each curve represents a median value of 10 tumors in each group. Transfection of
GLC19 cells with Ang-4 did not affect tumor growth. We found no difference in growth between GLC19-Ang-4 and GLC19-mock tumors. Bevacizumab treatment
significantly slowed tumor growth. Bars represent interquartile ranges. (B) IFP of subcutaneous tumors. All IFP recordings were carried out at tumor sizes of 600 to
1000 mm3. Each column represents a mean IFP of 12 to 17 tumors in each group. Data are expressed as mean ± SD.
Figure 4. Matrigel chambers and histology. (A and B) Digital photographs of Matrigel chambers with GLC19 SCLC cells (A) or the combination of GLC19 SCLC
cells and rhAng-4 (B). We found only limited red coloration in Ang-4– treated chambers. (C and D) Anti-CD31 immunohistochemical staining of ECs in Matrigel
chambers. Numerous structures inside GLC19 chambers were positively stained (C), whereas only sparse staining was seen in Ang-4– treated chambers (D). (E
and F) Anti-Ki67 staining of Matrigel chambers showed proliferating cells in both groups. (C and D) Arrows show vascular structures.
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doses of growth factors used in the experiments were based
on pilot studies with several doses and were in the same
order as those used by other groups [12,13].
In several repeated experiments, we found that Ang-4
inhibited EC migration. Both migration in the serum-free
medium and growth factor –stimulated migration were
inhibited by Ang-4. In a different experimental setup, Lee
et al. [12] found increased HUVEC migration on stimulation
with Ang-4. This dissimilarity may be due to differences in
culture conditions or in coating materials because both pa-
rameters can be crucial to the outcome of EC migration in
the Boyden chamber assay.
To evaluate the effect of Ang-4 on EC proliferation, we
used two different assays: RT-CES and computer-assisted
cell counting. We found no increase in HUVEC proliferation
after the addition of Ang-4. This is in accordance with pre-
vious findings [28].
The in vivo effect of Ang-4 may be site-specific or assay-
specific and may be influenced by local differences in micro-
environmental factors (e.g., growth factor levels). In our
setup, Ang-4 was tested in the presence of GLC19 tumor
cells, or of bFGF and VEGF in combination. Vessels in dif-
ferent regions of a tumor or in an experimental area of an
in vivo system might be exposed to entirely different levels of
VEGF and Ang. Ang-4 inhibited angiogenesis in the models
used in the present study.
The angiogenic response induced by tumor cells appears
to be more robust than the response induced by growth
factors alone. The continuous secretion of VEGF and bFGF
from tumor cells may cause higher local concentrations of
growth factors compared to the gradual release of recombi-
nant factors from the Matrigel chambers. Furthermore, se-
cretion from tumor cells in the chamber might increase as
cells proliferate, whereas the release of recombinant growth
factors is likely to decrease as the deposit in the chamber is
depleted. Moreover, tumor cells may produce other growth
factors in addition to VEGF and bFGF, and their presence
may constitute a proangiogenic stimulus as well.
The inhibitory effect of Ang-4 on angiogenesis driven by
recombinant growth factors, together with the observation of
a similar tumor cell proliferation in the treated and untreated
groups, indicates that angiogenesis is affected directly by
Ang-4 and not by toxicity in tumor cells. This is also sup-
ported by the similarity between the effects of Ang-4 and
bevacizumab in the Matrigel chambers.
There was no difference in growth rate between Ang-4–
transfected and mock-transfected tumor cells. Apparently,
Ang-4–induced inhibition of angiogenesis was not enough
to inhibit tumor growth. Angiogenesis was not completely
blocked by Ang-4 in the Matrigel chambers, and the remaining
angiogenesis was sufficient for the tumor to grow. Treatment
with bevacizumab significantly slowed tumor growth, as ex-
pected [29,30]. VEGF receptors are now known to be present
on some tumor cells [31–33]; accordingly, there may be
a direct effect of anti-VEGF therapy (e.g., bevacizumab) on
tumor cells themselves, which adds to the antiangiogenic ef-
fect. This might partly explain the observed difference in the
tumor growth effects of bevacizumab and Ang-4.
Increased vascular permeability contributes to elevated
IFP, which is characteristic of solid tumors [16,17]. VEGF is a
proleakage factor, and anti-VEGF treatment by bevacizumab
has been shown to reduce IFP in human tumor xenografts
[34] and in rectal cancer patients [35], most likely by anti-
leakage mechanisms as part of the vascular normalization
process. In accordance with what has previously been
shown, we observed a lower mean IFP in bevacizumab-
treated tumor xenografts. A lower tumor IFP is attractive as
it might increase the delivery of drugs to tumor cells [18]. In
this study, we show that Ang-4 decreases IFP in tumors to a
similar extent as treatment with bevacizumab. It has pre-
viously been shown that Ang-4 reduces thrombin-induced
increase in the permeability of EC monolayers [28]. Further-
more, in a murine model of acute lung injury, Ang-4 has
been shown to have a stabilizing effect on vessels, diminish-
ing capillary leakage [36]. In conjunction with our results,
these observations strongly indicate a reducing effect of
Ang-4 on vascular permeability. Vascular integrity may well
be regulated by a balance between proleakage factors
VEGF and Ang-2, and antileakage factors Ang-1 and
Ang-4. Thus, changes in any given factor may be less im-
portant than the overall balance between the proleakage and
antileakage factors.
In conclusion, our study shows that, in a human SCLC
tumor line, Ang-4 can contribute to the regulation of vascular
maturation and remodeling as an angiogenesis inhibitor and
as an antileakage factor.
Figure 6. (A) RT-PCR of cDNA from nine SCLC cell lines with primers specific for Ang-4. PCR products were separated on a 1.2% agarose gel and visualized by
ethidium bromide staining. A ladder was included as size control. (B) A protein isolated from subcutaneous tumor xenografts was used for Western blot analysis
with Ang-4 antibody. Ang-4 expression is retained in Ang-4– transfected GLC19 cells following growth in nude mice. Mock-transfected cells had no Ang-4 protein
expression. Equal loading was confirmed by a-tubulin detection. Control, recombinant Ang-4.
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